Cancer of Pancreas Clinical Trial
Official title:
Prognostic Importance of Quantitative Magnetic Resonance Imaging for Evaluation of Pancreatic Steatosis in Patients With Pancreatic Cancer
Prognostic Importance of Quantitative Magnetic Resonance Imaging for Evaluation of Pancreatic Steatosis in Patients with Pancreatic Cancer
Status | Recruiting |
Enrollment | 30 |
Est. completion date | October 2017 |
Est. primary completion date | September 2017 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - patients diagnosed with any pancreatic cancer, in any stage, before treatment. - >18 y.o Exclusion Criteria: - claustrophobia - GFR<30 - patients with non mri compatible devices (e.g. orthopaedic external fixation system) - After chemotherapy treatment or surgical procedure |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Israel | Soroka university medical center | Beer Sheva |
Lead Sponsor | Collaborator |
---|---|
Soroka University Medical Center |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of fat in pancreas measured in the head, body and tail excluding the lesion area. | measuring Pancreatic Steatosis in patients with pancreatic cancer using MRI DIXON scan, at 24 hours before chemotherapy starting. | at 24 hours before chemotherapy starting | No |
Primary | Blood levels of free DNA | Correlation of free DNA level and metastatic spread. | The blood sample taken 15 minutes prior to MRI study, at time of IV access. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02902484 -
Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04008537 -
Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device
|
N/A | |
Recruiting |
NCT04809935 -
EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy
|
Phase 4 | |
Not yet recruiting |
NCT03659292 -
Effects of Epidural Block on the Prognosis in Patients With Pancreatic Cancer Undergoing Distal Pancreatectomy
|
N/A | |
Completed |
NCT03150615 -
Enteral Nutrition After Pancreaticoduodenectomy
|
N/A | |
Recruiting |
NCT05566743 -
A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas
|
Phase 2 | |
Not yet recruiting |
NCT04049461 -
Heterotopic Ossification in Abdominal Incision and Pancreatic Cancer
|
||
Recruiting |
NCT04164602 -
The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly
|
||
Active, not recruiting |
NCT04128332 -
Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer
|
N/A | |
Recruiting |
NCT03536793 -
Tumour Regulatory Molecules in Early Pancreatic Cancer Detection
|
||
Recruiting |
NCT02311439 -
Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas
|
Phase 2/Phase 3 | |
Completed |
NCT02296736 -
The Pre-operative Pathway in Pancreatic Head Malignancy-assessment of the Diagnostic Accuracy of Staging CT Scan
|
||
Withdrawn |
NCT04123574 -
A Pilot Study of BXCL701 in Patients With Pancreatic Cancer
|
Early Phase 1 | |
Not yet recruiting |
NCT03278015 -
Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT02905578 -
A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
|
Phase 2 | |
Completed |
NCT01446458 -
Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT04677244 -
Echo-endoscopy Biopsy Impact on the Circulating Tumor Cell Level
|
N/A | |
Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
Recruiting |
NCT06148298 -
Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer
|
||
Terminated |
NCT03451773 -
M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas
|
Phase 1/Phase 2 |